Kyntra Bio, Inc. (KYNB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kyntra Bio, Inc. (KYNB) has a cash flow conversion efficiency ratio of -4.096x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.33 Million) by net assets ($4.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kyntra Bio, Inc. - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Kyntra Bio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Kyntra Bio, Inc. debt and liabilities for a breakdown of total debt and financial obligations.
Kyntra Bio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kyntra Bio, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Roblon A/S
CO:RBLN-B
|
0.020x |
|
Iconic Worldwide Bhd
KLSE:9113
|
-0.018x |
|
TBH Global Co Ltd
KO:084870
|
0.170x |
|
Proximar Seafood AS
OL:PROXI
|
-0.204x |
|
Highest Performances Holdings Inc.
NASDAQ:HPH
|
-0.004x |
|
Hamilton Global Opportunities PLC
PA:ALHGO
|
-0.012x |
|
NSC Groupe SA
PA:ALNSC
|
-0.028x |
|
Scienjoy Holding Corp
NASDAQ:SJ
|
0.008x |
Annual Cash Flow Conversion Efficiency for Kyntra Bio, Inc. (2012–2025)
The table below shows the annual cash flow conversion efficiency of Kyntra Bio, Inc. from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Kyntra Bio, Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.47 Million | $-4.77 Million | -1.067x | -241.96% |
| 2024-12-31 | $-183.63 Million | $-138.00 Million | 0.751x | -61.31% |
| 2023-12-31 | $-162.20 Million | $-315.02 Million | 1.942x | -98.03% |
| 2022-12-31 | $-1.48 Million | $-145.93 Million | 98.603x | +27572.66% |
| 2021-12-31 | $229.11 Million | $-82.23 Million | -0.359x | -294.16% |
| 2020-12-31 | $441.45 Million | $81.60 Million | 0.185x | +225.75% |
| 2019-12-31 | $535.41 Million | $-78.70 Million | -0.147x | -2.02% |
| 2018-12-31 | $528.47 Million | $-76.14 Million | -0.144x | -26.17% |
| 2017-12-31 | $582.45 Million | $-66.51 Million | -0.114x | -381.33% |
| 2016-12-31 | $175.11 Million | $7.11 Million | 0.041x | +143.02% |
| 2015-12-31 | $196.82 Million | $-18.57 Million | -0.094x | -201.31% |
| 2014-12-31 | $240.68 Million | $22.41 Million | 0.093x | -61.34% |
| 2013-12-31 | $107.60 Million | $25.92 Million | 0.241x | +625.07% |
| 2012-12-31 | $122.18 Million | $-5.61 Million | -0.046x | -- |
About Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible fact… Read more